NCT03278158View on ClinicalTrials.gov

A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

November 13, 2018

Study Completion Date

November 13, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Subjects in the placebo arm will receive a single oral tablet containing no active drug.

DRUG

XEN-D0501, 1 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet

DRUG

XEN-D0501, 2 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet

DRUG

XEN-D0501, 4 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet

DRUG

XEN-D0501, 8 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet

Trial Locations (1)

5000

Odense University Hospital, Odense

Sponsors

Lead Sponsor

Pila Pharma
All Listed Sponsors
lead

Pila Pharma

INDUSTRY

NCT03278158 - A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2 | Biotech Hunter | Biotech Hunter